文献速递外周动脉疾病

紫杉醇洗脱支架与药物涂层球囊治疗严重肢体缺血的保肢生存比较

Amputation-free Survival in Patients with Critical Limb Ischemia Treated with Paclitaxel-eluting Stents and Paclitaxel-coated Balloons.
PubMed 文献 · Ann Vasc Surg · 2019-06-15

该回顾性研究纳入88例Rutherford 5/6级严重肢体缺血患者,分别单独使用紫杉醇洗脱支架(DES,56例)或药物涂层球囊(DCB,32例)行腔内血运重建。12个月随访显示DES组无截肢生存率(88.5% vs 71.1%,P=0.0443)、伤口愈合率(83.9% vs 59.4%,P=0.0198)和一期通畅率(80.4% vs 58.1%,P=0.0255)均显著高于DCB组,而免于靶病变血运重建无差异。

要点

  • DES组12个月无截肢生存率88.5%,显著高于DCB组的71.1%(P=0.0443)。
  • DES组伤口愈合率83.9%,显著高于DCB组的59.4%(P=0.0198)。
  • DES组一期通畅率80.4%,显著高于DCB组的58.1%(P=0.0255)。

核心结论

  • 紫杉醇DES治疗严重肢体缺血的12个月无截肢生存率、伤口愈合率和一期通畅率均显著优于紫杉醇DCB。

研究设计与样本

  • 单中心回顾性队列研究,纳入4年间接受紫杉醇类技术(DES或DCB)腔内血运重建的Rutherford 5/6级严重肢体缺血患者。
  • 共88例患者88条肢体,DES组56例(60.7%男性,中位年龄70.5岁),DCB组32例(46.9%男性,中位年龄66岁)。
  • 按意向性治疗分析,随访至术后12个月,主要终点为12个月无截肢生存率。

主要发现

  • DES组与DCB组12个月无截肢生存率分别为88.5%和71.1%(P=0.0443)。
  • DES组与DCB组1年伤口愈合率分别为83.9%和59.4%(P=0.0198)。
  • DES组与DCB组免于靶病变血运重建率分别为90.6%和85.7%(P=0.518),无显著差异。
  • DES组与DCB组12个月一期通畅率分别为80.4%和58.1%(P=0.0255)。
  • 基线除DES组靶病变闭塞比例更高外(41.1% vs 12.5%,P=0.004),其余人口学特征匹配良好。

关键数值与推荐

  • 靶病变通畅定义为双功超声速度比≤2且狭窄<50%。
  • 肢体缺血程度按Rutherford分级和WIfI评分系统评估。
  • Rutherford 5级占71.6%,6级占28.4%。

临床怎么用

  • 对于严重肢体缺血患者,紫杉醇DES在保肢生存、伤口愈合和通畅率方面可能优于DCB,但需结合病变特征和操作者判断个体化选择。

局限性

  • 非随机、异质性队列,治疗选择基于操作者最佳判断,可能存在选择偏倚。
  • 样本量较小(共88例),DES组与DCB组基线靶病变闭塞比例存在显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate the performance of paclitaxel-eluting stents (PESs) and paclitaxel-coated balloons (PCBs) on amputation-free survival in patients with critical limb ischemia (CLI). METHODS: A retrospective review of all patients with Rutherford stage 5 and 6 limb ischemia undergoing endovascular revascularization with paclitaxel-related technology, both PES and PCB, was carried out over a 4-year period. Clinical grading was determined by Rutherford classification and the Society for Vascular Surgery's Wound, Ischemia, and foot Infection (WIfI) scoring system. Clinical and angiographic follow-up was reviewed based on intention-to-treat analysis. The primary endpoint of this study was amputation-free survival at 12 months. Secondary endpoints included wound healing, freedom from target lesion revascularization, and patency of target vessels at 12 months. Follow-up occurred at 3, 6, and 12 months postoperatively. Target lesion patency was defined as <50% stenosis, based on a duplex velocity ratio of less than or equal to 2. Postoperative ankle-brachial index (ABI) and duplex ultrasound were performed to verify successful treatment. Outcomes were evaluated using Kaplan-Meier and Cox proportional-hazards models. RESULTS: A total of 88 limbs were revascularized in 88 patients. Drug-eluting stent (DES) was used as the sole drug technology in 56 patients (60.7% men, median age 70.5 years) and drug-coated balloon (DCB) was used as the sole drug technology in 32 patients (46.9% men, median age 66 years). Baseline demographics were well matched except for a higher prevalence of occluded target lesions in the DES group (41.1% vs. 12.5%; P = 0.004). Limbs were treated for Rutherford stage 5 CLI in 71.6% and stage 6 CLI in 28.4%. Univariate analysis identified no dependent factors affecting limb salvage, except for the use of DCBs. After 12 months of follow-up, amputation-free survival was significantly higher in the DES group than in the DCB group (88.5% vs. 71.1%; P = 0.0443). Wound healing rates after 1 year were also higher in the DES group (83.9% vs. 59.4%; P = 0.0198). Freedom from target lesion revascularization was no different between patients treated with DESs and patients treated with DCBs (90.6% vs. 85.7%; P = 0.518). Primary patency at 12 months in patients treated with DESs was significantly higher than in patients treated with PCBs (80.4% vs. 58.1%; P = 0.0255). CONCLUSIONS: Overall, drug technology represents a viable option for patients with CLI; a cohort not represented in major randomized trials. In our experience, femoropopliteal lesions treated with DESs have higher primary patency rates than those treated with DCBs. This was found to support higher amputation-free survival rates in patients treated with paclitaxel DESs than those treated with paclitaxel DCB. The use of paclitaxel DESs for CLI was also associated with significantly improved wound healing compared with DCBs. Our data suggest improved outcomes with DESs compared with DCBs; however, these patients represent a nonrandomized, heterogenous group that were treated with the operator's best judgment.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Phair J, Carnevale M, Lipsitz EC, et al. Amputation-free Survival in Patients with Critical Limb Ischemia Treated with Paclitaxel-eluting Stents and Paclitaxel-coated Balloons. Ann Vasc Surg. 2019. PMID: 31207400. doi:10.1016/j.avsg.2019.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。